a Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories , Hamilton , MT , USA.
Hum Vaccin Immunother. 2018;14(9):2107-2113. doi: 10.1080/21645515.2018.1473698. Epub 2018 Jun 18.
The devastating Ebola virus (EBOV) epidemic in West Africa in 2013-2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1-3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine.
2013-2016 年西非发生的毁灭性埃博拉病毒（EBOV）疫情加速了几种疫苗和抗病毒药物的临床试验进程，包括复制型水疱性口炎病毒载体表达埃博拉病毒糖蛋白（VSV-EBOV）疫苗。该疫苗在动物模型中的广泛临床前测试证明了其预防和暴露后疗效，确定了其保护机制，并表明其对人类使用是安全的。基于这些数据，VSV-EBOV 在北美、欧洲和非洲的 1-3 期临床试验中进行了广泛测试。尽管观察到一些疫苗接种的副作用，但这些临床试验表明 VSV-EBOV 在人类中是安全且具有免疫原性的。此外，这些数据支持将 VSV-EBOV 用作埃博拉病毒病高危人群的紧急疫苗。在这篇综述中，我们总结了 VSV-EBOV 疫苗的广泛临床前和临床测试结果。
Zotero 插件